Laboratory characterization of leukemic cell procoagulants

Renáta Hudák, Ildikó Beke Debreceni, Ivett Deák, Gabriella Gál Szabó, Zsuzsanna Hevessy, Péter Antal-Szalmás, Bjarne Osterud, János Kappelmayer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In acute myeloid leukemias, there is an increased chance to develop thrombotic disorders. We hypothesized that in addition to leukemic promyelocytes, monocytic leukemia cells may also have a higher procoagulant activity. Fibrin formation was assessed by a one-stage clotting assay using a magnetic coagulometer. The thrombin generation test (TGT) of magnetically isolated normal human monocytes, intact leukemic cells and their isolated microparticles was performed by a fluorimetric assay. Phosphatidylserine (PS) expression of leukemic cells and microparticle number determinations were carried out by flow cytometry. All cell lines displayed a significant procoagulant potential compared to isolated normal human monocytes. In the TGT test, the mean of lagtime and the time to peak parameters were significantly shorter in leukemic cells (3.9-4.7 and 9.9-10.3 min) compared to monocytes (14.9 and 26.5 min). The mean of peak thrombin in various monocytic leukemia cell lines was 112.1-132.9 nM vs. 75.1 nM in monocytes; however, no significant difference was observed in the ETP parameter. Factor VII-deficient plasma abolished all procoagulant activity, whereas factor XII-deficient plasma did not affect the speed of fibrin formation and thrombin generation but modulated the amount of thrombin. Factor XI-deficient plasma affected the time to peak values in one leukemic cell line and also attenuated peak thrombin. Leukemia cell-derived microparticles from all three cell lines exerted a procoagulant effect by significantly shortening the lagtime in TGT; there was a nonsignificant difference in case of ETP parameter. All investigated monocytic leukemia cell lines exhibited significant thrombin generation. This phenomenon was achieved by the procoagulants on the surface of leukemic cells as well as by their microparticles.

Original languageEnglish
Pages (from-to)1215-1223
Number of pages9
JournalClinical Chemistry and Laboratory Medicine
Volume55
Issue number8
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Thrombin
Cells
Monocytes
Leukemia
Cell Line
Fibrin
Plasmas
Assays
Cell-Derived Microparticles
Factor XI
Factor XII
Granulocyte Precursor Cells
Factor VII
Flow cytometry
Phosphatidylserines
Acute Myeloid Leukemia
Flow Cytometry
Thermodynamic properties
Cell Count

Keywords

  • monocytic leukemia
  • procoagulant activity
  • thrombin generation
  • tissue factor

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Laboratory characterization of leukemic cell procoagulants. / Hudák, Renáta; Debreceni, Ildikó Beke; Deák, Ivett; Szabó, Gabriella Gál; Hevessy, Zsuzsanna; Antal-Szalmás, Péter; Osterud, Bjarne; Kappelmayer, János.

In: Clinical Chemistry and Laboratory Medicine, Vol. 55, No. 8, 01.07.2017, p. 1215-1223.

Research output: Contribution to journalArticle

Hudák, Renáta ; Debreceni, Ildikó Beke ; Deák, Ivett ; Szabó, Gabriella Gál ; Hevessy, Zsuzsanna ; Antal-Szalmás, Péter ; Osterud, Bjarne ; Kappelmayer, János. / Laboratory characterization of leukemic cell procoagulants. In: Clinical Chemistry and Laboratory Medicine. 2017 ; Vol. 55, No. 8. pp. 1215-1223.
@article{54d744cba95348b1b7160cf2fd919638,
title = "Laboratory characterization of leukemic cell procoagulants",
abstract = "In acute myeloid leukemias, there is an increased chance to develop thrombotic disorders. We hypothesized that in addition to leukemic promyelocytes, monocytic leukemia cells may also have a higher procoagulant activity. Fibrin formation was assessed by a one-stage clotting assay using a magnetic coagulometer. The thrombin generation test (TGT) of magnetically isolated normal human monocytes, intact leukemic cells and their isolated microparticles was performed by a fluorimetric assay. Phosphatidylserine (PS) expression of leukemic cells and microparticle number determinations were carried out by flow cytometry. All cell lines displayed a significant procoagulant potential compared to isolated normal human monocytes. In the TGT test, the mean of lagtime and the time to peak parameters were significantly shorter in leukemic cells (3.9-4.7 and 9.9-10.3 min) compared to monocytes (14.9 and 26.5 min). The mean of peak thrombin in various monocytic leukemia cell lines was 112.1-132.9 nM vs. 75.1 nM in monocytes; however, no significant difference was observed in the ETP parameter. Factor VII-deficient plasma abolished all procoagulant activity, whereas factor XII-deficient plasma did not affect the speed of fibrin formation and thrombin generation but modulated the amount of thrombin. Factor XI-deficient plasma affected the time to peak values in one leukemic cell line and also attenuated peak thrombin. Leukemia cell-derived microparticles from all three cell lines exerted a procoagulant effect by significantly shortening the lagtime in TGT; there was a nonsignificant difference in case of ETP parameter. All investigated monocytic leukemia cell lines exhibited significant thrombin generation. This phenomenon was achieved by the procoagulants on the surface of leukemic cells as well as by their microparticles.",
keywords = "monocytic leukemia, procoagulant activity, thrombin generation, tissue factor",
author = "Ren{\'a}ta Hud{\'a}k and Debreceni, {Ildik{\'o} Beke} and Ivett De{\'a}k and Szab{\'o}, {Gabriella G{\'a}l} and Zsuzsanna Hevessy and P{\'e}ter Antal-Szalm{\'a}s and Bjarne Osterud and J{\'a}nos Kappelmayer",
year = "2017",
month = "7",
day = "1",
doi = "10.1515/cclm-2017-0021",
language = "English",
volume = "55",
pages = "1215--1223",
journal = "Clinical Chemistry and Laboratory Medicine",
issn = "1434-6621",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "8",

}

TY - JOUR

T1 - Laboratory characterization of leukemic cell procoagulants

AU - Hudák, Renáta

AU - Debreceni, Ildikó Beke

AU - Deák, Ivett

AU - Szabó, Gabriella Gál

AU - Hevessy, Zsuzsanna

AU - Antal-Szalmás, Péter

AU - Osterud, Bjarne

AU - Kappelmayer, János

PY - 2017/7/1

Y1 - 2017/7/1

N2 - In acute myeloid leukemias, there is an increased chance to develop thrombotic disorders. We hypothesized that in addition to leukemic promyelocytes, monocytic leukemia cells may also have a higher procoagulant activity. Fibrin formation was assessed by a one-stage clotting assay using a magnetic coagulometer. The thrombin generation test (TGT) of magnetically isolated normal human monocytes, intact leukemic cells and their isolated microparticles was performed by a fluorimetric assay. Phosphatidylserine (PS) expression of leukemic cells and microparticle number determinations were carried out by flow cytometry. All cell lines displayed a significant procoagulant potential compared to isolated normal human monocytes. In the TGT test, the mean of lagtime and the time to peak parameters were significantly shorter in leukemic cells (3.9-4.7 and 9.9-10.3 min) compared to monocytes (14.9 and 26.5 min). The mean of peak thrombin in various monocytic leukemia cell lines was 112.1-132.9 nM vs. 75.1 nM in monocytes; however, no significant difference was observed in the ETP parameter. Factor VII-deficient plasma abolished all procoagulant activity, whereas factor XII-deficient plasma did not affect the speed of fibrin formation and thrombin generation but modulated the amount of thrombin. Factor XI-deficient plasma affected the time to peak values in one leukemic cell line and also attenuated peak thrombin. Leukemia cell-derived microparticles from all three cell lines exerted a procoagulant effect by significantly shortening the lagtime in TGT; there was a nonsignificant difference in case of ETP parameter. All investigated monocytic leukemia cell lines exhibited significant thrombin generation. This phenomenon was achieved by the procoagulants on the surface of leukemic cells as well as by their microparticles.

AB - In acute myeloid leukemias, there is an increased chance to develop thrombotic disorders. We hypothesized that in addition to leukemic promyelocytes, monocytic leukemia cells may also have a higher procoagulant activity. Fibrin formation was assessed by a one-stage clotting assay using a magnetic coagulometer. The thrombin generation test (TGT) of magnetically isolated normal human monocytes, intact leukemic cells and their isolated microparticles was performed by a fluorimetric assay. Phosphatidylserine (PS) expression of leukemic cells and microparticle number determinations were carried out by flow cytometry. All cell lines displayed a significant procoagulant potential compared to isolated normal human monocytes. In the TGT test, the mean of lagtime and the time to peak parameters were significantly shorter in leukemic cells (3.9-4.7 and 9.9-10.3 min) compared to monocytes (14.9 and 26.5 min). The mean of peak thrombin in various monocytic leukemia cell lines was 112.1-132.9 nM vs. 75.1 nM in monocytes; however, no significant difference was observed in the ETP parameter. Factor VII-deficient plasma abolished all procoagulant activity, whereas factor XII-deficient plasma did not affect the speed of fibrin formation and thrombin generation but modulated the amount of thrombin. Factor XI-deficient plasma affected the time to peak values in one leukemic cell line and also attenuated peak thrombin. Leukemia cell-derived microparticles from all three cell lines exerted a procoagulant effect by significantly shortening the lagtime in TGT; there was a nonsignificant difference in case of ETP parameter. All investigated monocytic leukemia cell lines exhibited significant thrombin generation. This phenomenon was achieved by the procoagulants on the surface of leukemic cells as well as by their microparticles.

KW - monocytic leukemia

KW - procoagulant activity

KW - thrombin generation

KW - tissue factor

UR - http://www.scopus.com/inward/record.url?scp=85025106391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025106391&partnerID=8YFLogxK

U2 - 10.1515/cclm-2017-0021

DO - 10.1515/cclm-2017-0021

M3 - Article

VL - 55

SP - 1215

EP - 1223

JO - Clinical Chemistry and Laboratory Medicine

JF - Clinical Chemistry and Laboratory Medicine

SN - 1434-6621

IS - 8

ER -